Depression to ecstasy. The Neuropharmacology of Serotonin sponsored by the New York Academy of Sciences, New York, NY, USA, July 10-13, 1989.
Whitaker-Azmitia
P M
PM
Department of Psychiatry and Behavioral Science, SUNY, Stony Brook 11794-8101.
D015104:3,4-Methylenedioxyamphetamine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D000818:Animals; D001931:Brain Mapping; D003863:Depression / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D001523:Mental Disorders / Q000378:metabolism; D008881:Migraine Disorders / Q000188:drug therapy / Q000503:physiopathology; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D009473:Neuronal Plasticity; D010146:Pain / Q000503:physiopathology; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology; D012701:Serotonin / Q000502:physiology*; D012702:Serotonin Antagonists / Q000494:pharmacology; D012737:Sex Factors; D012890:Sleep / Q000502:physiology; D013329:Structure-Activity Relationship
D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D012701:Serotonin; D015104:3,4-Methylenedioxyamphetamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine